Evidence map›Paper›PMID 41078144›Full record

ArticleMolecular pharmaceutics2025

Arabinogalactan-Functionalized Gold Nanoparticles Demonstrated Remarkable Anticancer Therapeutic Effect against Hepatocellular Carcinoma.

Vasumathi R, Maya P Shetty, Suvalakshmi S, Revathi P Shenoy, Srinivas Mutalik, Sanjay Bharati

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vasumathi RDepartment of Nuclear Medicine, Manipal College of Health Professions, Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India.
Maya P ShettyDepartment of Nuclear Medicine, Manipal College of Health Professions, Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India.
Suvalakshmi SDepartment of Nuclear Medicine, Manipal College of Health Professions, Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India.
Revathi P ShenoyDepartment of Biochemistry, Kasturba Medical College, Manipal Academy of higher education, Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India.
Srinivas MutalikDepartment of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India.ORCID 0000-0002-0642-1928
Sanjay BharatiDepartment of Nuclear Medicine, Manipal College of Health Professions, Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India.ORCID 0000-0002-3697-2632

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment and prognosis of cancer remain highly challenging due to its complex and multifaceted nature. In the paradigm of nanomedicine, nanotechnology has gained huge attention in cancer therapeutics. The unique physicochemical properties offered by gold nanoparticles (AuNPs) in targeted drug delivery and anticancer therapy favor their implications in cancer therapeutics. However, surface modification, particularly with polysaccharides, can further optimize the function of gold nanoparticles. Among others, the advantages offered by arabinogalactan (AG) make it a suitable candidate for coating gold nanoparticles. The present study reported the anticancer therapeutic potential of AG-AuNPs against liver cancer. The synthesized AG-AuNPs were characterized for UV-visible spectrum, hydrodynamic size, zeta potential, core size, bonding and functional groups, crystalline nature, and elemental composition. The compound was then evaluated for its stability in biological fluids followed by

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularGalactansGoldLiver NeoplasmsMetal NanoparticlesAnimalsCell Line, TumorDrug Delivery SystemsHumansMaleMiceRatsTissue DistributionAntineoplastic AgentsarabinogalactanGalactansGoldactive targetingasialoglycoprotein receptorsgold nanoparticlesHepatocellular carcinomapassive targeting

Identifiers

PMID41078144
PMCPMC12587396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.